Phase 3 RedeS Hits Primary Endpoint, Paving Path for INTERCEPT Red Blood Cells
CERS sits 70% above its 52-week low of $1.38.
Summary
Cerus reported positive topline Phase 3 RedeS results for its INTERCEPT Blood System for red blood cells, the last major untapped market for its pathogen-reduction platform. The primary efficacy endpoint was met: adjusted hemoglobin increment was 1.996 g/dL in the INTERCEPT arm versus 2.050 g/dL in the control arm, a difference of -0.054 g/dL with the 95% confidence interval lower bound above the prespecified non-inferiority margin (p=0.004). Safety looked manageable — transfusion-related adverse events were 3.4% versus 2.5% (not significant), and INTERCEPT-specific antibodies appeared in 2.2% of treated patients versus none in controls, with no hemolysis or clinical impact. This is the pivotal data point for a company with a roughly $474M market cap whose approved products cover only platelets, plasma and cryoprecipitation; RBCs would materially expand the addressable market. The FDA has not reviewed the full study report and the RBC system remains investigational in the U.S., so approval is not assured. Full secondary-endpoint data will be submitted to a peer-reviewed journal and presented at upcoming scientific meetings; management discusses the results on a 4:30 P.M. ET call alongside Q3 2026 results.
At the time of this announcement, CERS was trading at $2.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $473.6M. The 52-week trading range was $1.38 to $3.47. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.